LB Pharmaceuticals (NASDAQ:LBRX) Hits New 52-Week High - What's Next?

Key Points

• LB Pharmaceuticals hit a new 52‑week high, trading as high as $33.47 and last at $31.81 (up about 3.5%) on volume of 242,280 shares, with a market capitalization of roughly $912.3 million.
• Analysts are mostly bullish: several brokerages have initiated or raised coverage with buy ratings and price targets ranging from $31 to $45, leaving a MarketBeat consensus of "Moderate Buy" and an average target of $37.20.
• Company fundamentals and investor interest: LBRX is a clinical‑stage biopharma advancing LB‑102 for neuropsychiatric disorders, reported a loss of $0.45 EPS last quarter (matching estimates) and faces expected negative FY EPS, while several institutional investors (including JPMorgan and Commodore) have recently taken stakes.

LB Pharmaceuticals Inc (NASDAQ:LBRX - Get Free Report)'s stock price hit a new 52-week high during trading on Tuesday . The stock traded as high as $33.47 and last traded at $31.81, with a volume of 242280 shares changing hands. The stock had previously closed at $30.73.

Wall Street Analysts Forecast Growth

Several brokerages have commented on LBRX. HC Wainwright began coverage on shares of LB Pharmaceuticals in a report on Monday. They issued a "buy" rating and a $45.00 price target for the company. Craig Hallum began coverage on shares of LB Pharmaceuticals in a report on Friday, April 10th. They issued a "buy" rating and a $36.00 price target for the company. Stifel Nicolaus raised their price target on shares of LB Pharmaceuticals from $35.00 to $40.00 and gave the company a "buy" rating in a report on Friday, March 27th. Roth Mkm initiated coverage on LB Pharmaceuticals in a research report on Friday, January 9th. They set a "buy" rating and a $31.00 price target for the company. Finally, Weiss Ratings reiterated a "sell (e)" rating on shares of LB Pharmaceuticals in a research report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, LB Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $37.20.

LB Pharmaceuticals Trading Up 3.5%

The company has a market capitalization of $912.31 million and a P/E ratio of -30.01. The business's fifty day moving average price is $25.69 and its 200-day moving average price is $21.51.

LB Pharmaceuticals (NASDAQ:LBRX - Get Free Report) last posted its quarterly earnings data on Thursday, March 26th. The company reported ($0.45) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.45). As a group, equities research analysts forecast that LB Pharmaceuticals Inc will post -3.85 EPS for the current year.

Institutional Trading of LB Pharmaceuticals

A number of hedge funds have recently bought and sold shares of LBRX. Boxer Capital Management LLC purchased a new stake in LB Pharmaceuticals in the third quarter worth approximately $1,105,000. Nan Fung Group Holdings Ltd purchased a new stake in LB Pharmaceuticals in the third quarter worth approximately $4,737,000. JPMorgan Chase & Co. purchased a new stake in LB Pharmaceuticals in the third quarter worth approximately $16,305,000. Commodore Capital LP purchased a new stake in LB Pharmaceuticals in the third quarter worth approximately $23,685,000. Finally, Integral Health Asset Management LLC purchased a new stake in LB Pharmaceuticals in the third quarter worth approximately $1,579,000.

About LB Pharmaceuticals

We are a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. We are building a pipeline that leverages the broad therapeutic potential of our lead product candidate, LB-102, which we believe has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries, not including the United States, because the development and regulatory requirements of the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.